文献

J-GLOBAL ID：202202273253274960   整理番号：22A1070910

SARS-CoV-2を中和するカシリビマブ-イムデビマブ:注射後の臨床イベントとそれらの危険因子

Casirivimab-imdevimab neutralizing SARS-CoV-2: post-infusion clinical events and their risk factors

著者 (8件)： Junichi Yoshida, (Infection Control Committee, Shimonoseki City Hospital, Shimonoseki, Japan) ,  Kenichiro Shiraishi, (Department of Medicine and Biosystemic Science, Kyushu University Faculty of Medicine, Fukuoka, Japan) ,  Tetsuro Tamura, (Infection Control Committee, Shimonoseki City Hospital, Shimonoseki, Japan) ,  Kazuhiro Otani, (Infection Control Committee, Shimonoseki City Hospital, Shimonoseki, Japan) ,  Tetsuya Kikuchi, (Infection Control Committee, Shimonoseki City Hospital, Shimonoseki, Japan) ,  Akiko Mataga, (Infection Control Committee, Shimonoseki City Hospital, Shimonoseki, Japan) ,  Takako Ueno, (Infection Control Committee, Shimonoseki City Hospital, Shimonoseki, Japan) ,  Masao Tanaka, (Infection Control Committee, Shimonoseki City Hospital, Shimonoseki, Japan)
資料名： Journal of Pharmaceutical Health Care and Sciences (Web)  (Journal of Pharmaceutical Health Care and Sciences (Web))
巻： 8  号： 1  ページ： 1-5  発行年： 2022年 
JST資料番号： U1100A  ISSN： 2055-0294  資料種別： 逐次刊行物 (A)
記事区分： 短報  発行国： イギリス (GBR)  言語： 英語 (EN)

抄録/ポイント： SARS-CoV-2を中和するために,カシリビマブ-イムデビ...

シソーラス用語： *モノクローナル抗体 ,...
準シソーラス用語： *COVID-19 ,...

ログイン（無料）して見る     続きはJDreamIII（有料）にて  {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=22A1070910&from=J-GLOBAL&jstjournalNo=U1100A") }}

著者キーワード (5件)： SARS-CoV-2 ,  カリビマブ ,  インデビマブ ,  発熱 ,  低酸素

分類 (2件)： 抗ウイルス薬の臨床への応用  (GW17050Z) ,  感染症・寄生虫症の治療  (GD01030D)

引用文献 (15件)：

• N Engl J Med; REGN-COV2, a neutralizing antibody cocktail, in outpatients with Covid-19; DM Weinreich, S Sivapalasingam, T Norton, S Ali, H Gao, R Bhore, BJ Musser, Y Soo, D Rofail, J Im, C Perry, C Pan, R Hosain, A Mahmood, JD Davis, KC Turner, AT Hooper, JD Hamilton, A Baum, CA Kyratsous, Y Kim, A Cook, W Kampman, A Kohli, Y Sachdeva, X Graber, B Kowal, T DiCioccio, N Stahl, L Lipsich, N Braunstein, G Herman, GD Yancopoulos; 384; 3; 2021; 238-251; 10.1056/NEJMoa2035002; citation_id=CR1
• Infectious Disease Society of America. Guideline. Immunomodulators. Last reviewed: September 3, 2021.https://www.idsociety.org/covid-19-real-time-learning-network/therapeutics-and-interventions/immunomodulators/. Accessed 18 Sep 2021.
• Pharmaceuticals and Medical Devices Agency. FACT SHEET FOR HEALTH CARE PROVIDERS EMERGENCY USE AUTHORIZATION (EUA) OF REGEN-COVTM (casirivimab and imdevimab) AUTHORIZED USE.https://www.pmda.go.jp/drugs/2021/P20210719001/450045000_30300AMX00310_B100_1.pdf. Accessed 18 Sep 2021.
• U.S. Food and Drug Administration. FACT SHEET FOR HEALTH CARE PROVIDERS EMERGENCY USE AUTHORIZATION (EUA) OF REGEN-COV® (casirivimab and imdevimab).https://www.fda.gov/media/145611/download. Accessed 18 Sep 2021.
• National Institute of Infectious Diseases of Japan. Current Situation of Infection, September 1, 2021. 50th meeting of the COVID-19 advisory board of Ministry of Health, Labour and Welfare (September 1, 2021).https://wwwniidgojp/niid/en/2019-ncov-e/10636-covid19-ab50th-enhtml. Accessed 18 Sep 2021.

タイトルに関連する用語 (6件)： SARS-CoV-2 ,  中和 ,  注射 ,  臨床 ,  イベント ,  危険因子